{"id":"W4306247391","doi":"10.1016/s2213-2600(22)00309-5","title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Jazz Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Servier; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemotherapy; Population; Febrile neutropenia; Oncology; Doxorubicin; Topotecan; Vincristine; Anthracycline; Clinical trial; Surgery; Cyclophosphamide; Cancer; Neutropenia; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246748,0.0002599088,0.001061804,0.0001865267,0.0002059974,0.00001323214,0.0004022027,0.00004347189,0.0001277982],"category_scores_gemma":[0.0003771536,0.0001600351,0.00002832191,0.0007252877,0.0003029393,0.00009852791,0.000231803,0.0005911167,5.115501e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003616209,"about_ca_system_score_gemma":0.0002522663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009420719,"about_ca_topic_score_gemma":0.0002292334,"domain_scores_codex":[0.9973686,0.0004492195,0.0004928445,0.0004066947,0.0008541009,0.0004285116],"domain_scores_gemma":[0.998098,0.0006984684,0.0003819512,0.0004938365,0.0002180823,0.0001096678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.929752,0.003010796,0.03931009,0.0004614395,0.0004844434,0.00002714141,0.002229447,0.00002131819,0.005644782,0.00004953119,0.01452034,0.004488662],"study_design_scores_gemma":[0.9544728,0.01099527,0.02518866,0.0004006765,0.0003233149,3.924453e-7,0.000345977,0.0004311722,0.0008256343,0.000005025798,0.006835998,0.0001750778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985546,0.003452217,0.000003527832,0.003316657,0.0004280298,0.005930043,0.00003719618,0.00003160142,0.001254749],"genre_scores_gemma":[0.9955657,0.0004398198,0.00002644296,0.002102522,0.0006036481,0.0009386576,0.00004652032,0.00004639359,0.0002302727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02472079,"threshold_uncertainty_score":0.652604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0657955502563836,"score_gpt":0.3892918764154446,"score_spread":0.323496326159061,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}